CIITA and neoplasm: A combination of existing immunotherapeutic approaches, such as immune-checkpoint inhibitors or oncolytic viruses, with MHC-II expression transcriptionally enhanced by CIITA in cancer cells could potentially increase the recognition of tumor antigen and effector T-cell activation [44].